BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

臺大醫院-內科部;Mok, T. S. K.T. S. K.MokLee, J. S.J. S.LeeZhang, L.L.ZhangYu, C.C.YuThongprasert, S.S.ThongprasertLadrera, G. E. I.G. E. I.LadreraSrimuninnimit, V.V.SrimuninnimitTruman, M. I.M. I.TrumanKlughammer, B.B.KlughammerWu, Y.Y.Wu2014-02-142018-07-112014-02-142018-07-112012http://ntur.lib.ntu.edu.tw//handle/246246/25906682 bytestext/html[SDGs]SDG3BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)http://ntur.lib.ntu.edu.tw/bitstream/246246/259066/1/index.html